MedTech Insights: “This is a pivotal year for us,” says VeinWay CEO
With seven compassionate-use cases under its belt and commercialization in view, VeinWay—developer of the Traversa, a tool for crossing tough venous occlusions—is at a...
CX 2024 venous programme has “a lot to look forward to,” says executive board
Erin Murphy (Atrium Health’s Sanger Heart and Vascular Institute, Charlotte, USA), one of the CX Symposium cochairs and a CX Executive Board member, along...
CX 2024: Dive into the Venous and Lymphatic Podium Firsts
Manj Gohel (Cambridge, UK), member of the Venous Executive Board, parachutes straight into the CX Venous and Lymphatics Controversies Programme to highlight the VenaSeal SPECTRUM...
In the making: Data-driven venous care
The quest for more data—specifically multicenter, independently adjudicated and, where possible, randomized—in the field of venous disease continues, with various trials currently underway set...
